Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMYT Amryt Pharma (AMYT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Amryt Pharma Stock (NASDAQ:AMYT) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Amryt Pharma alerts:Sign Up Key Stats Today's Range$14.63▼$14.7650-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume2.39 million shsAverage Volume757,360 shsMarket Capitalization$940.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesAlembic Pharmaceuticals Ltd.October 13, 2023 | wsj.comAMYT Historical DataOctober 10, 2023 | investing.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Beijing Sun-Novo Pharmaceutical Research Co. Ltd. AJuly 28, 2023 | wsj.com2022 for Chiesi: The Group’s international growth continuesApril 11, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementApril 3, 2023 | finance.yahoo.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsMarch 17, 2023 | benzinga.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023February 16, 2023 | finance.yahoo.comSee More Headlines AMYT Stock Analysis - Frequently Asked Questions How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.66. The business earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Block (SQ) and Tesla (TSLA). Company Calendar Last Earnings11/05/2020Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMYT CUSIPN/A CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.22 Cash Flow$0.98 per share Price / Cash Flow14.98 Book Value$5.58 per share Price / Book2.63Miscellaneous Outstanding Shares63,960,000Free Float60,343,000Market Cap$940.21 million OptionableNot Optionable Beta0.84 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AMYT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.